Dolutegravir Reduces Human T-Cell Lymphotropic Virus Type 1 Proviral Load and Improves Neurological Outcomes in a Phase 2 Controlled Trial. (academic.oup.com)

Authors: Brites C … Netto EM Journal: Clinical Infectious Diseases Published: 2026-05-20 DOI: https://doi.org/10.1093/cid/ciag163